Log in to your Inderes Free account to see all free content on this page.
Gubra
612
DKK
+1.32 %
GUBRA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+1.32%
+0.33%
-1.92%
+46.76%
-2.55%
+343.48%
-
-
+456.36%
Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.
Read moreMarket cap
10.01B DKK
Turnover
13.83M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Coverage
Latest research
Latest analysis report
Released: 09.09.2024
Financial calendar
28.2.
2025
Annual report '24
ShowingAll content types
Gubra Announces New Collaboration with Amylyx Pharmaceuticals to Develop a Novel Long-acting GLP-1 Receptor Antagonist
Gubra announces positive GUBamy Phase 1 SAD data (correction)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Gubra announces positive GUBamy Phase 1 SAD data

Gubra: Wrap up from Q3 event with CEO Henrik Blou and CFO Kristian Borbos

Gubra – Presentation of Q3 2024

Gubra: Another strong quarter in CRO and pipeline update
Trading statement Q3-2024: Another strong quarter

Gubra: Shares drop 4% yesterday amid pipeline news, despite the news relating to a smaller part of our pipeline valuation
Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim

Gubra (One pager): Obesity Market Upgrade Enhances DCF Estimates
Major shareholder announcement

Gubra - Presentation of Q2 report 2024
Interim report H1 2024: Strong performance across Gubra
Gubra raises financial outlook for 2024
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares
